JP2018538308A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018538308A5 JP2018538308A5 JP2018532038A JP2018532038A JP2018538308A5 JP 2018538308 A5 JP2018538308 A5 JP 2018538308A5 JP 2018532038 A JP2018532038 A JP 2018532038A JP 2018532038 A JP2018532038 A JP 2018532038A JP 2018538308 A5 JP2018538308 A5 JP 2018538308A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- antibody
- use according
- bladder
- aqueous solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 37
- 239000007788 liquid Substances 0.000 claims 6
- 238000000034 method Methods 0.000 claims 6
- 206010005003 Bladder cancer Diseases 0.000 claims 4
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 4
- 238000009098 adjuvant therapy Methods 0.000 claims 4
- 239000007864 aqueous solution Substances 0.000 claims 4
- 201000005112 urinary bladder cancer Diseases 0.000 claims 4
- -1 hexyl 5-ALA ester Chemical class 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 3
- 238000009799 cystectomy Methods 0.000 claims 2
- 238000009099 neoadjuvant therapy Methods 0.000 claims 1
- 229960003301 nivolumab Drugs 0.000 claims 1
- 229960002621 pembrolizumab Drugs 0.000 claims 1
- 238000002271 resection Methods 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1522311.8 | 2015-12-17 | ||
| GBGB1522311.8A GB201522311D0 (en) | 2015-12-17 | 2015-12-17 | Use |
| PCT/EP2016/081798 WO2017103280A1 (en) | 2015-12-17 | 2016-12-19 | Intravesical therapy for bladder cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018538308A JP2018538308A (ja) | 2018-12-27 |
| JP2018538308A5 true JP2018538308A5 (enExample) | 2020-02-06 |
Family
ID=55311161
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018532038A Pending JP2018538308A (ja) | 2015-12-17 | 2016-12-19 | 膀胱癌のための膀胱内療法 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20180371101A1 (enExample) |
| EP (1) | EP3390448B1 (enExample) |
| JP (1) | JP2018538308A (enExample) |
| KR (1) | KR102878726B1 (enExample) |
| CN (1) | CN108699147B (enExample) |
| AU (1) | AU2016372570B2 (enExample) |
| DK (1) | DK3390448T3 (enExample) |
| ES (1) | ES2981986T3 (enExample) |
| FI (1) | FI3390448T3 (enExample) |
| GB (1) | GB201522311D0 (enExample) |
| PL (1) | PL3390448T3 (enExample) |
| WO (1) | WO2017103280A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6869987B2 (ja) | 2015-09-01 | 2021-05-12 | アジェナス インコーポレイテッド | 抗ｐｄ−１抗体及びその使用方法 |
| GB201522311D0 (en) * | 2015-12-17 | 2016-02-03 | Photocure Asa | Use |
| CN110300599B (zh) | 2016-12-07 | 2024-07-02 | 艾吉纳斯公司 | 抗体和其使用方法 |
| US11266619B2 (en) * | 2017-12-01 | 2022-03-08 | Sbi Pharmaceuticals Co., Ltd. | Pharmaceutical composition for enhancing antitumor effect by immune checkpoint inhibitor |
| KR20250154511A (ko) | 2023-03-07 | 2025-10-28 | 포토큐어 에이에스에이 | 방광암 치료 |
| WO2026052815A1 (en) | 2024-09-05 | 2026-03-12 | Photocure Asa | Use of hal in a method for predicting bladder cancer immunotherapy response |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE122006000051I1 (de) | 1995-03-10 | 2007-01-04 | Photocure Asa | Ester der 5-Aminolevulins{ure als Mittel zur Photosensibillisierung in der Chemotherapie |
| DE60334303D1 (de) | 2002-07-03 | 2010-11-04 | Tasuku Honjo | Immunpotenzierende zusammensetzungen |
| GB0406917D0 (en) | 2004-03-26 | 2004-04-28 | Photocure Asa | Compounds |
| PT2170959E (pt) | 2007-06-18 | 2014-01-07 | Merck Sharp & Dohme | Anticorpos para o receptor humano de morte programada pd-1 |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| WO2010036959A2 (en) * | 2008-09-26 | 2010-04-01 | Dana-Farber Cancer Institute | Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor |
| MX356367B (es) | 2008-12-09 | 2018-05-25 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t. |
| BR112014002353B1 (pt) | 2011-08-01 | 2022-09-27 | Genentech, Inc | Usos de antagonistas de ligação do eixo pd-1 e inibidores de mek, composições farmacêuticas, e kit |
| BR112014012819B1 (pt) | 2011-11-28 | 2022-08-16 | Merck Patent Gmbh | Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição |
| ES2742379T3 (es) | 2012-05-31 | 2020-02-14 | Hoffmann La Roche | Procedimientos de tratamiento del cáncer usando antagonistas de unión al eje de PD-1 y antagonistas de VEGF |
| JP6954648B2 (ja) * | 2015-10-19 | 2021-10-27 | シージー オンコロジー， インコーポレイテッド | 併用療法による固形腫瘍又はリンパ系腫瘍の治療方法 |
| GB201522309D0 (en) * | 2015-12-17 | 2016-02-03 | Photocure Asa | Use |
| GB201522311D0 (en) * | 2015-12-17 | 2016-02-03 | Photocure Asa | Use |
-
2015
- 2015-12-17 GB GBGB1522311.8A patent/GB201522311D0/en not_active Ceased
-
2016
- 2016-12-19 CN CN201680079683.1A patent/CN108699147B/zh active Active
- 2016-12-19 ES ES16819062T patent/ES2981986T3/es active Active
- 2016-12-19 AU AU2016372570A patent/AU2016372570B2/en active Active
- 2016-12-19 JP JP2018532038A patent/JP2018538308A/ja active Pending
- 2016-12-19 WO PCT/EP2016/081798 patent/WO2017103280A1/en not_active Ceased
- 2016-12-19 DK DK16819062.7T patent/DK3390448T3/da active
- 2016-12-19 PL PL16819062.7T patent/PL3390448T3/pl unknown
- 2016-12-19 EP EP16819062.7A patent/EP3390448B1/en active Active
- 2016-12-19 US US16/063,169 patent/US20180371101A1/en not_active Abandoned
- 2016-12-19 KR KR1020187020008A patent/KR102878726B1/ko active Active
- 2016-12-19 FI FIEP16819062.7T patent/FI3390448T3/fi active
-
2019
- 2019-04-18 US US16/388,379 patent/US11066478B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2013121788A (ru) | Ингибиторы репликации вич | |
| RU2012118974A (ru) | Комбинации ингибитора pi3k и ингибитора мек | |
| EA201792541A3 (ru) | Ингибиторы рециркуляции желчных кислот для лечения гиперхолемии и холестатического заболевания печени | |
| AR072442A1 (es) | Metodo para la terapia del cancer, uso, kit | |
| FI3390448T3 (fi) | Intravesikaalinen hoito virtsarakon syöpää varten | |
| CR20190247A (es) | Métodos para el tratamiento de la atrofia muscular y enfermedad ósea con el uso de proteínas trap híbridas novedosas del ligando actriib | |
| RU2018146886A (ru) | Пути терапевтического применения ингибитора c-raf | |
| EA201390840A1 (ru) | Полициклический lpaантагонист и его применение | |
| EA201391263A1 (ru) | Комбинированные терапии гематологических опухолей | |
| FI3484446T3 (fi) | Vasta-ainekoostumuksia | |
| IL311873A (en) | Combination therapy for treating malignancies | |
| ATE553772T1 (de) | Verwendung von lvv-hämorphin-6 und optional af12198 als therapeutische(s) mittel | |
| EA201592287A1 (ru) | Замещенные тетрагидрокарбазольные и карбазолкарбоксамидные соединения | |
| AU2020256847B2 (en) | Method of treating tumours | |
| SI2945620T1 (en) | Nitroxyl donors with improved therapeutic index | |
| JP2018537514A5 (enExample) | ||
| JP2020502198A5 (enExample) | ||
| FI3463436T3 (fi) | Rokote yhdistelmänä immuunivasteen tarkastuspisteen estäjän kanssa käytettäväksi hoidettaessa syöpää | |
| RU2014145841A (ru) | Терапевтический биопрепарат для лечения гепатоцеллюлярной карциномы | |
| KR102787188B1 (ko) | 방광암에 대한 신보조 요법 | |
| JP2012522841A5 (enExample) | ||
| AR084216A1 (es) | Composiciones y metodos para tratar el cancer usando un inhibidor de pi3k e inhibidor de mek, kit | |
| JP2019501161A5 (enExample) | ||
| RU2018123834A (ru) | Способ фотодинамической терапии (фдт) для рака мочевого пузыря | |
| EA201491870A1 (ru) | Способ лечения гиперурикемии у больных подагрой с помощью галофената или галофеновой кислоты и противовоспалительного агента |